Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bayer Aktiengesellschaft (BAYRY : OTC)
 
 • Company Description   
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.

Number of Employees: 99,637

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.94 Daily Weekly Monthly
20 Day Moving Average: 470,507 shares
Shares Outstanding: 3,929.70 (millions)
Market Capitalization: $66,569.05 (millions)
Beta: 1.11
52 Week High: $18.45
52 Week Low: $12.45
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.47% 3.51%
12 Week 12.93% 26.92%
Year To Date 27.75% 56.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Kaiser-Wilhelm-Allee 1
-
Leverkusen,2M 51368
DEU
ph: 49-21-4-30-1
fax: 49-21-4306-6328
peter.dahlhoff@bayer.com http://www.bayer.com
 
 • General Corporate Information   
Officers
Werner Baumann - Chief executive officer and Chairman
Wolfgang Nickl - Finance
Hartmut Klusik - Human Resources; Technology
Kemal Malik - Innovation
M. Arnold - Corporate Office

Peer Information
Bayer Aktiengesellschaft (AGN.)
Bayer Aktiengesellschaft (ABBV)
Bayer Aktiengesellschaft (NVO)
Bayer Aktiengesellschaft (LLY)
Bayer Aktiengesellschaft (RHHBY)
Bayer Aktiengesellschaft (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 072730302
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 3,929.70
Most Recent Split Date: 9.00 (4.00:1)
Beta: 1.11
Market Capitalization: $66,569.05 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.08%
Current Fiscal Quarter EPS Consensus Estimate: $0.48 Indicated Annual Dividend: $0.35
Current Fiscal Year EPS Consensus Estimate: $1.95 Payout Ratio: 0.19
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: -0.08
Estmated Long-Term EPS Growth Rate: 3.97% Last Dividend Paid: 05/02/2022 - $0.35
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 8.69
Trailing 12 Months: 7.92
PEG Ratio: 2.19
Price Ratios
Price/Book: 1.70
Price/Cash Flow: 5.95
Price / Sales: 1.24
EPS Growth
vs. Year Ago Period: 26.92%
vs. Previous Quarter: 175.00%
Sales Growth
vs. Year Ago Period: 10.53%
vs. Previous Quarter: 29.18%
ROE
03/31/22 - 22.39
12/31/21 - 19.63
09/30/21 - 20.52
ROA
03/31/22 - 6.06
12/31/21 - 5.42
09/30/21 - 5.60
Current Ratio
03/31/22 - -
12/31/21 - 1.11
09/30/21 - 1.11
Quick Ratio
03/31/22 - -
12/31/21 - 0.72
09/30/21 - 0.74
Operating Margin
03/31/22 - 15.68
12/31/21 - 14.56
09/30/21 - 15.05
Net Margin
03/31/22 - 4.29
12/31/21 - 2.17
09/30/21 - 0.34
Pre-Tax Margin
03/31/22 - -
12/31/21 - 4.64
09/30/21 - 4.08
Book Value
03/31/22 - -
12/31/21 - 9.99
09/30/21 - 9.38
Inventory Turnover
03/31/22 - -
12/31/21 - 1.57
09/30/21 - 1.61
Debt-to-Equity
03/31/22 - -
12/31/21 - 1.10
09/30/21 - 1.18
Debt-to-Capital
03/31/22 - -
12/31/21 - 52.38
09/30/21 - 54.18
 

Powered by Zacks Investment Research ©